Suppr超能文献

肺癌患者行肺楔形切除术治疗原位腺癌或微浸润性腺癌的 10 年随访结果:楔形切除术可达到根治性效果。

Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative.

机构信息

Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China; Institute of Thoracic Oncology, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Institute of Thoracic Oncology, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.

出版信息

J Thorac Cardiovasc Surg. 2022 Dec;164(6):1614-1622.e1. doi: 10.1016/j.jtcvs.2022.06.017. Epub 2022 Jul 5.

Abstract

OBJECTIVE

This study aimed to reveal the long-term outcomes of patients with lung cancer with adenocarcinoma in situ or minimally invasive adenocarcinoma after resection, in the context of the different surgical resection types.

METHODS

Patients with lung adenocarcinoma who underwent resection between December 2007 and December 2012 were reviewed. Patients with pathological adenocarcinoma in situ or minimally invasive adenocarcinoma were enrolled. Postoperative survival and risk of developing second primary lung cancer were analyzed.

RESULTS

After reevaluating the histological findings of 1696 patients with lung adenocarcinoma, we enrolled 53 with adenocarcinoma in situ and 72 with minimally invasive adenocarcinoma for analyses. Of all 125 patients with adenocarcinoma in situ/minimally invasive adenocarcinoma, 86 (68.8%) were female, 114 (91.2%) were nonsmokers, and most of them (78, 62.4%) underwent wedge resection. The median follow-up period after surgery was 111 months. The 10-year recurrence-free survivals of adenocarcinoma in situ and minimally invasive adenocarcinoma were all 100%, and the 10-year overall survivals of adenocarcinoma in situ and minimally invasive adenocarcinoma were 98.1% and 97.2%, respectively. There was no difference in 10-year recurrence-free survival between patients who underwent lobectomy and wedge resection. EGFR mutations were detected in 63.1% (41/65) of patients who underwent mutational analysis. The risks of developing second primary lung cancer for adenocarcinoma in situ and minimally invasive adenocarcinoma 10 years after resection were 8.4% and 4.3% (P = .298), respectively, and were not correlated with EGFR mutation status (P = .525).

CONCLUSIONS

Pathological adenocarcinoma in situ and minimally invasive adenocarcinoma have no recurrence during 10-year follow-up after resection, regardless of surgical procedure types. Surgery is curative for these patients, and wedge resection is the preferred surgical procedure for nodules in the proper location.

摘要

目的

本研究旨在探讨不同手术切除类型背景下,肺腺癌原位癌或微浸润性腺癌患者的长期预后。

方法

回顾性分析 2007 年 12 月至 2012 年 12 月期间接受手术切除的肺腺癌患者,纳入病理诊断为腺癌原位癌或微浸润性腺癌的患者。分析术后生存及第二原发肺癌发生风险。

结果

在重新评估 1696 例肺腺癌患者的组织学发现后,我们纳入了 53 例原位腺癌和 72 例微浸润性腺癌进行分析。在所有 125 例原位癌/微浸润性腺癌患者中,86 例(68.8%)为女性,114 例(91.2%)为不吸烟者,其中 78 例(62.4%)接受楔形切除术。术后中位随访时间为 111 个月。原位癌和微浸润性腺癌的 10 年无复发生存率均为 100%,原位癌和微浸润性腺癌的 10 年总生存率分别为 98.1%和 97.2%。行肺叶切除术和楔形切除术的患者 10 年无复发生存率无差异。对 65 例患者进行突变分析,其中 63.1%(41/65)检测到 EGFR 突变。术后 10 年,原位癌和微浸润性腺癌发生第二原发肺癌的风险分别为 8.4%和 4.3%(P=0.298),与 EGFR 突变状态无关(P=0.525)。

结论

术后 10 年随访时,病理诊断为原位癌和微浸润性腺癌的患者无复发,无论手术类型如何。手术对这些患者是治愈性的,楔形切除术是合适部位结节的首选手术方式。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验